Homocysteine is linked to macular edema in type 2 diabetes

Current Eye Research

Volumn 39, Issue 7, 2014, Pages 730-735

  Li, Jianbo ^a,b   Zhang, Hongman ^a   Shi, Min ^a   Yan, Lingfei ^a   Xie, Min ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic macular edema; Homocysteine; Risk factor; Type 2 diabetes

Indexed keywords

BIGUANIDE; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HEMOGLOBIN A1C; HOMOCYSTEINE; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DISEASE DURATION; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FOLIC ACID BLOOD LEVEL; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; BLOOD; CHINA; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOASSAY; INCIDENCE; MACULAR EDEMA; MIDDLE AGED; PATHOLOGY; PHOTOMETRY; PROGNOSIS; PROSPECTIVE STUDY; QUESTIONNAIRE; RETINA;

ADULT; AGED; BIOLOGICAL MARKERS; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HOMOCYSTEINE; HUMANS; IMMUNOASSAY; INCIDENCE; MACULAR EDEMA; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RETINA; RISK FACTORS;

EID: 84901832995     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.877933     Document Type: Article

References (30)

1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al.; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-1101.
2. Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010;26: 1587-1597.
3. Seddon JM, Gensler G, Klein ML, Milton RC. C-reactive protein and homocysteine are associated with dietary and behavioral risk factors for age-related macular degeneration. Nutrition 2006; 22:441-443.
4. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-oxidized hydrogen peroxide generation from homocysteine. Clin Invest 1986;77:1370-1376.
5. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelial-derived relaxing factor and related oxides of nitrogen. Clin Invest 1993;91:308-318.
6. Abdella NA, Mojiminiyi OA, Akanji AO, Moussa MA. Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetol 2002;39:183-190.
7. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001;73:613-621.
8. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998;41:684-693.
9. Storch KJ, Wagner DA, Young VR. Methionine kinetics in adult men: effects of dietary betaine on L-[2H3-methyl- 1-13C]methionine. Am J Clin Nutr 1991;54:386-934.
10. Baines M, Kredan MB, Usher J, Davison A, Higgins G, Taylor W, et al. The association of homocysteine and its determinants: MTHFR genotype, folate, vitamin B12 and vitamin B6 with bone mineral density in postmenopausal British women. Bone 2007;40:730-736.
11. Ganji V, Kafai MR. Demographic, lifestyle, and health characteristics and serum B vitamin status are determinants of plasma total homocysteine concentration in the post-folic acid fortification period, 1999-2004. J Nut 2009; 139:345-352.
12. Elias AN, Eng S. Homocysteine concentrations in patients with diabetes mellitus-relationship to microvascular and macrovascular disease. Diabetes Obes Metab 2005;7: 117-121.
13. Aydin E, Demir HD, Ozyurt H, Etikan I. Association of plasma homocysteine and maculopathy in type 2 diabetes mellitus. Eur J Ophthalmol 2008;18:226-232.
14. Klein BE, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol 2009;127:1175-1182.
15. WHO: World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva: World Health Org, 2006.
16. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for Diabetic Maculopathy. Arch Ophthalmol 1985;103:1796-1806.
17. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677-1682.
18. Vivian F, Evan MB, Lawrence B, Kenneth C, Marjorie LC, Hertzel CG, et al. Summary of revisions for the 2006 Clinical practice recommendations. Diabetes Care 2006;29:S3.
19. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:1482-1483.
20. Hao L, Ma J, Zhu J, Stampfer MJ, Tian Y, Willett WC, et al. Vitamin B-12 deficiency is prevalent in 35- to 64-year-old Chinese adults. J Nutr 2007;137:1278-1285.
21. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Eng J Med 2008;359:1577-1589.
22. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
23. Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Diabet Med 2008;25: 860-862.
24. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004;10:3395-3418.
25. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic maculopathy: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011; 31:298-303.
26. Reddy GB, Satyanarayana A, Balakrishna N, Ayyagari R, Padma M, Viswanath K, et al. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol Vis 2008;14:593-601.
27. Mao R, Fan Y, Chen F, Fu S. Genetic polymorphism of MTHFR G1793A in Chinese populations. Eur J Epidemiol 2008;23:363-368.
28. Chan E, Fonseca VA. Management of hyperhomocysteinemia. Metab Syndr Relat Disord 2003;1:159-170.
29. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303:1603-1609.
30. Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan 2005;14:48-54.